Dr. Bruce Trapnell
Dr. Bruce Trapnell is a physician-scientist whose work spans biochemistry, genetics, internal medicine, and pulmonary medicine. As a professor of medicine and pediatrics at the University of Cincinnati and Scientific Director of the Pulmonary Alveolar Proteinosis Foundation, he has spent more than three decades working to understand and treat rare diseases, including cystic fibrosis, alpha-1 antitrypsin deficiency, and autoimmune pulmonary alveolar proteinosis (aPAP). His work on aPAP and GM-CSF diagnostics and therapies has helped advance understanding and treatment of the disease while addressing challenges common across rare diseases: small patient populations, uncertainty, and limited access to education and resources. Throughout his career, Dr. Trapnell has brought together basic science, clinical research, and patient advocacy to turn scientific discoveries into meaningful progress for patients.
If there was one person who changed the way Dr. Bruce Trapnell thinks about rare disease research, he points to John Walsh, an individual who lived with Alpha-1 antitrypsin deficiency and the founder of the Alpha-1 Foundation. Dr. Trapnell described John as magnetic, forward thinking, industrious, entrepreneurial and engaging. “John Walsh did more for Alpha-1 lung disease than any other patient I know of did for any other rare lung disease” explained Dr. Trapnell as he described John’s commitment to educating patients and providers on improving quality of care for Alpha-1. Dr. Trapnell first became involved with the foundation in the early 2000s. What began as an opportunity to contribute to a research project became much more meaningful, a firsthand lesson in what one patient could accomplish for an entire rare disease community. Since then, John Walsh has passed away, but continues to influence Dr. Trapnell’s work. Through his involvement with the Alpha-1 Foundation, Dr. Trapnell helped establish a research grant program that has distributed more than $100 million in research funding for Alpha-1.
“In rare diseases, you make progress one person at a time,” said Dr. Trapnell.
In rare disease research, progress depends on finding individuals, listening to them and learning from their experiences. Each patient adds another piece of information. Each interaction can raise a new question, reveal something researchers did not understand, or help point toward what needs to happen next. Dr. Trapnell described the relationship as a partnership because individuals living with rare diseases are often searching for someone who will first listen to them, to hear their story long enough to make sense of what they are experiencing, and help determine what comes next. Meanwhile, researchers and physicians are trying to understand the underlying biology and find ways to diagnose and treat the disease.
That perspective, that patient and providers can push the scientific community forward together, has shaped the way Dr. Bruce Trapnell approaches treatment development. For years, one of the main ways to help people with PAP was a procedure called whole-lung lavage. The treatment can provide quick relief, but it is invasive and does not correct the underlying problem. During the procedure, doctors place a tube into each lung, mechanically ventilate one lung while treating the other, and fill the treated lung with warmed saline. The patient’s chest is then repeatedly percussed to loosen the material that has accumulated inside the air sacs. The fluid is drained and the process repeated, sometimes using as much as 50 liters of saline in a single lung. “It doesn’t fix the problem, and it doesn’t stop the accumulation,” he explained. His current research has helped identify that antibodies against GM-CSF disrupt the lung’s ability to clear surfactant, leading to the buildup seen in aPAP patients. That discovery pointed to a different approach: inhaled GM-CSF, which helps restore the body’s signaling to the lungs needed to clear the material. While whole-lung lavage remains important for patients who need rapid relief, there are other options that can target the underlying biology of the disease and potentially reduce the need for invasive procedures.
For Dr. Bruce Trapnell, the most meaningful part of his work is not a single scientific milestone, but helping patients replace uncertainty with answers. He has seen the field move from understanding aPAP in the laboratory, to diagnosing it in patients, to developing reliable testing and potential new therapies. As the FDA considers the data for inhaled GM-CSF, the potential significance extends beyond a new therapy. For patients with aPAP, it could offer a treatment aimed at correcting the underlying problem rather than repeatedly removing what has accumulated. As a caregiver from the Voice of the Patient Report explains, “This drug may not eliminate the need for lung lavages but even getting to a point of only needing one every 10 years is better than what we have now.” Progress that has been made possible through persistence and collaboration with the patient community. While treatment continues to evolve, Dr. Trapnell’s philosophy remains the same: listen to patients, follow the evidence, and keep working together to move rare disease research forward.
Who’s made a difference in your rare disease? Whether it’s a teacher, parent, pastor, friend, or physician, if you want to recognize someone who has impacted your life, click here to nominate them!
- NORD. Voice of the Patient Report: Autoimmune Pulmonary Alveolar Proteinosis (aPAP). May 15, 2026.
